TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17964402

Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Acetazolamide 250 mg
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Intracameral acetylcholine
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Timolol 0.5%
Number of subjects: 185

Group type: COMPARATOR
Intervention: No ocular hypotensive agent (control group)
Number of subjects: 185
Study: 16547381

Group type: EXPERIMENTAL
Intervention: Indomethacin (INDO) 0.2‐0.2‐0.2 mg/kg
Number of subjects: 35

Group type: COMPARATOR
Intervention: Ibuprofen (IBU) 10‐5‐5 mg/kg
Number of subjects: 35

Group type: COMPARATOR
Intervention: Ibuprofen (IBU)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Indomethacin (INDO)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Indomethacin (INDO) with hydrocortisone
Number of subjects: 35
Study: 12133653

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 203

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 203
Study: 10875825

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 5499
Study: 9359536

Group type: EXPERIMENTAL
Intervention: bezafibrate (200 mg 3 times daily)
Number of subjects: 92

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: bezafibrate
Number of subjects: 92
Study: 8201912

Group type: EXPERIMENTAL
Intervention: Voltaren sustained release, 100 mg once a day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nodo regular formulation, 200 mg once a day
Number of subjects: 20
Study: 3018564

Group type: EXPERIMENTAL
Intervention: 0.5 ml of intramuscular iodized oil
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 51
Study: 29235557

Group type: COMPARATOR
Intervention: Fetal-neonatal ID (n=253)
Number of subjects: 1194

Group type: COMPARATOR
Intervention: Infancy ID (n=288)
Number of subjects: 1194

Group type: COMPARATOR
Intervention: Fetal-neonatal and infancy ID (n=256)
Number of subjects: 1194

Group type: COMPARATOR
Intervention: More severe ID in late pregnancy
Number of subjects: 1194

Group type: COMPARATOR
Intervention: More severe ID in infancy
Number of subjects: 1194
Study: 27783129

Group type: EXPERIMENTAL
Intervention: Continuity of care (frequent contact with mental health services)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Changes in care coordinator
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Clinical correspondence copied to patients
Number of subjects: 323
Study: 24800313

Group type: EXPERIMENTAL
Intervention: Brief, exposure-based intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 40
Study: 23103835

Group type: EXPERIMENTAL
Intervention: Online unguided self-help intervention consisting of 6 modules based on cognitive behavioral techniques.
Number of subjects: 236

Group type: COMPARATOR
Intervention: Waitlist, information-only control group.
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Online unguided self-help intervention.
Number of subjects: 236
Study: 20426866

Group type: EXPERIMENTAL
Intervention: Maintenance Cognitive Stimulation Therapy (CST) for 24 weeks after initial CST for 7 weeks
Number of subjects: 230

Group type: COMPARATOR
Intervention: Cognitive Stimulation Therapy (CST) for 7 weeks followed by treatment as usual for 24 weeks
Number of subjects: 230
Study: 18617301

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg twice daily for eGFR 30 to 60 mL/min/1.73 m² or once daily for eGFR 10 to 29 mL/min/1.73 m²)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control (Losartan only)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (in second stage for both groups)
Number of subjects: 85
Study: 15845706

Group type: EXPERIMENTAL
Intervention: Hypocapnia (Paco(2) 27‐34 mm Hg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normocapnia (Paco(2) 38‐43 mm Hg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hypocapnia
Number of subjects: 12
Study: 11921456

Group type: EXPERIMENTAL
Intervention: Tobramycin solution for inhalation (TSI) 300 mg b.i.d. for 24 weeks
Number of subjects: 520

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 520
Study: 10209810

Group type: EXPERIMENTAL
Intervention: Covariate adjustment in group randomized trials
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Blocking communities according to covariates
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Covariate adjustment
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Design of group randomized trials
Number of subjects: 4
Study: 8949327

Group type: EXPERIMENTAL
Intervention: Whispered voice test
Number of subjects: 62

Group type: COMPARATOR
Intervention: Four simple tests for screening for hearing loss
Number of subjects: 62
Study: 1741572

Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Polytherapy
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Phenobarbital, Carbamazepine, Polytherapy
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Calcium, Parathyroid hormone, Osteocalcine
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Treatment duration over 3 years
Number of subjects: 98
Study: 30920874

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injected on the buccal aspect of supporting teeth
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no PRP treatment)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: PRP group
Number of subjects: 18
Study: 28928319

Group type: EXPERIMENTAL
Intervention: Ask, Brief, Cessation support (ABC) package
Number of subjects: 156

Group type: COMPARATOR
Intervention: Existing standard of care
Number of subjects: 156
Study: 26061140

Group type: EXPERIMENTAL
Intervention: AAV2-neurturin injected bilaterally into the substantia nigra (2.0 × 10(11) vector genomes) and putamen (1.0 × 10(12) vector genomes)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 51
Study: 23490060

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 3405

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3405
Study: 21098317

Group type: EXPERIMENTAL
Intervention: Ferric gluconate 187.5 mg IV every 3 weeks
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Oral daily ferrous sulfate 325 mg
Number of subjects: 502

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Ferric gluconate IV
Number of subjects: 502
Study: 19675481

Group type: EXPERIMENTAL
Intervention: Contrast Water Therapy (C(T)WT)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Active Recovery (ACT)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Passive Recovery
Number of subjects: 10
Study: 17376239

Group type: EXPERIMENTAL
Intervention: Proximal occlusion
Number of subjects: 26

Group type: COMPARATOR
Intervention: Distal occlusion
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Proximal method
Number of subjects: 26

Group type: COMPARATOR
Intervention: Distal method
Number of subjects: 26
Study: 15017207

Group type: EXPERIMENTAL
Intervention: Sextant biopsies recommended when total PSA was 3 ng/ml or greater at screening rounds 1 and 2, and 2.54 ng/ml or greater at subsequent screening rounds.
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Total core cancer length of less than 3 mm.
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Total core cancer length greater than 10 mm.
Number of subjects: 10000
Study: 11249885

Group type: EXPERIMENTAL
Intervention: Direct stent implantation (DS+)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Standard stent implantation with balloon predilatation (DS-)
Number of subjects: 338
Study: 9487256

Group type: EXPERIMENTAL
Intervention: Cyclical etidronate treatment
Number of subjects: 7977

Group type: COMPARATOR
Intervention: Control group (osteoporosis patients not taking etidronate)
Number of subjects: 7977
Study: 7961544

Group type: EXPERIMENTAL
Intervention: Newer antidepressants (SSRIs, venlafaxine, bupropion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Older tricyclic antidepressants
Number of subjects: 0
Study: 2665146

Group type: EXPERIMENTAL
Intervention: Retroperitoneal approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transperitoneal approach
Number of subjects: 0
Study: 1184167

Group type: EXPERIMENTAL
Intervention: 5% glucose
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 5% fructose
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 5% xylitol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 5% xylitol-glucose-fructose
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 5% sorbitol
Number of subjects: 60
Study: 31009695

Group type: EXPERIMENTAL
Intervention: Oxygen therapy targeting an SpO2 of 90–94% (intervention)
Number of subjects: 1416

Group type: COMPARATOR
Intervention: Oxygen therapy targeting an SpO2 of 98–100% (control)
Number of subjects: 1416
Study: 29325319

Group type: EXPERIMENTAL
Intervention: Half-dose spectral CT based on GSI Assist with 50% ASIR (group A)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Conventional CT with 120 kVp and 30% ASIR (group B)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Half-dose spectral CT (group A)
Number of subjects: 82
Study: 25410205

Group type: EXPERIMENTAL
Intervention: Single oral dose of Peru-15 pCTB vaccine at dosages of 1 ×10(7), 1 ×10(8), 1 ×10(9), and 1 ×10(10) CFU
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Single oral dose of Peru-15 pCTB vaccine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (buffer alone)
Number of subjects: 60
Study: 23539756

Group type: EXPERIMENTAL
Intervention: Early parenteral nutrition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Late parenteral nutrition
Number of subjects: 0
Study: 21181601

Group type: EXPERIMENTAL
Intervention: Negative photographic portrayals of an obese person
Number of subjects: 188

Group type: COMPARATOR
Intervention: Positive photographic portrayals of an obese person
Number of subjects: 188

Group type: COMPARATOR
Intervention: No photograph
Number of subjects: 188
Study: 18955454

Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m² every 3 weeks plus lapatinib 1,500 mg/d
Number of subjects: 579

Group type: COMPARATOR
Intervention: Paclitaxel plus placebo
Number of subjects: 579
Study: 16939990

Group type: EXPERIMENTAL
Intervention: HFA‐BDP
Number of subjects: 22

Group type: COMPARATOR
Intervention: Fluticasone DPI
Number of subjects: 22
Study: 14503779

Group type: EXPERIMENTAL
Intervention: Nursing home residents with medical and social factors leading to admission
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Nursing home residents assessed for malnutrition and health conditions
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Nursing home residents with mental health assessments
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Nursing home residents with chronic conditions
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Nursing home residents assessed for cognitive impairment
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Nursing home residents assessed for functional abilities
Number of subjects: 106
Study: 10758783

Group type: EXPERIMENTAL
Intervention: Methylprednisolon‐ratiopharm 8 mg tablets (test preparation)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Reference preparation 8 mg tablets (control)
Number of subjects: 16
Study: 8824106

Group type: EXPERIMENTAL
Intervention: gemfibrozil (1200 mg/day)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: simvastatin (20 mg/day)
Number of subjects: 81
Study: 1358133

Group type: EXPERIMENTAL
Intervention: Nisoldipine 10 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 3976757

Group type: EXPERIMENTAL
Intervention: 17 alpha-hydroxyprogesterone caproate, 250 mg by intramuscular injection once a week
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 27726108

Group type: EXPERIMENTAL
Intervention: Teaching session combining visual aids and practical exercises
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study: 27474857

Group type: EXPERIMENTAL
Intervention: Implementation intention condition
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control instruction condition
Number of subjects: 50
Study: 24352580

Group type: EXPERIMENTAL
Intervention: Extraction group (n=86)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Non-extraction group (n=263)
Number of subjects: 349
Study: 22622851

Group type: EXPERIMENTAL
Intervention: Vaginal combination therapy including 500 mg metronidazole and 100 mg miconazole nitrate two times a day for 7 days
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control group (no preoperative vaginal therapy)
Number of subjects: 192
Study: 20547012

Group type: EXPERIMENTAL
Intervention: Decisional balance proportion (DBP) change scores posttreatment-pretreatment
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Decisional balance proportion (DBP) change scores
Number of subjects: 191
Study: 18230792

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 16
Study: 15611838

Group type: EXPERIMENTAL
Intervention: Fascia transversalis repair (FTR)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Lichtenstein mesh repair
Number of subjects: 180

Group type: COMPARATOR
Intervention: Preperitoneal mesh repair
Number of subjects: 180
Study: 14569243

Group type: EXPERIMENTAL
Intervention: Heart rate recovery 1 minute after exercise
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Heart rate recovery
Number of subjects: 304
Study: 10619824

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (500 microg twice daily)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Dexamethasone (in vitro studies)
Number of subjects: 15
Study: 8858403

Group type: EXPERIMENTAL
Intervention: Exercise (E)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 12
Study: 1495520

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 6090
Study: 6712851

Group type: EXPERIMENTAL
Intervention: Naloxone 0.006 mg kg‐1 5 min before induction of anaesthesia
Number of subjects: 2

Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 2
Study: 30595056

Group type: EXPERIMENTAL
Intervention: Four-session smoking intervention based on the theory of planned behavior and life skills training.
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (101 students).
Number of subjects: 106
Study: 27836715

Group type: EXPERIMENTAL
Intervention: Improvisation Theater (IT) program, 60 min sessions weekly for 12 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (CS)
Number of subjects: 22
Study: 26581787

Group type: EXPERIMENTAL
Intervention: Resistance training (once- or twice-weekly)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Twice-weekly resistance training
Number of subjects: 155

Group type: COMPARATOR
Intervention: Balance-and-toning (twice-weekly)
Number of subjects: 155
Study: 23886521

Group type: EXPERIMENTAL
Intervention: Lidocaine 1mg/mL
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Lidocaine 10mg/mL
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 22044855

Group type: EXPERIMENTAL
Intervention: Antiretroviral (ARV) regimens/strategies
Number of subjects: 4630
Study: 19382010

Group type: EXPERIMENTAL
Intervention: Paroxetine controlled release (CR) 12.5-62.5 mg/day
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Paroxetine controlled release (CR)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 112
Study: 17005075

Group type: EXPERIMENTAL
Intervention: Quyu Xiaoban Capsule (QYXBC) for 10 months
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 42
Study: 12725259

Group type: EXPERIMENTAL
Intervention: Heparin in addition to antisnake venom (ASV)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group (no heparin)
Number of subjects: 122
Study: 11382658

Group type: EXPERIMENTAL
Intervention: Vitamin A + Zinc
Number of subjects: 202

Group type: COMPARATOR
Intervention: Zinc alone
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202

Group type: COMPARATOR
Intervention: Vitamin A alone (Placebo for Zinc)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Beta-carotene + Zinc
Number of subjects: 202

Group type: COMPARATOR
Intervention: Beta-carotene alone
Number of subjects: 202
Study: 9542610

Group type: COMPARATOR
Intervention: Mite-allergic patients
Number of subjects: 75

Group type: COMPARATOR
Intervention: Grass pollen-allergic patients (out of season)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Grass pollen-allergic patients (intraseasonal)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Comparison of intraseasonal grass pollen-allergic patients to mite-allergic patients
Number of subjects: 75
Study: 7909642

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia (Group S)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia (Group E)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combined spinal and epidural anaesthesia (Group SE)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Prehydration with balanced electrolyte solution
Number of subjects: 24

Group type: COMPARATOR
Intervention: Apgar score and acid-base status of umbilical artery and vein
Number of subjects: 24
Study: 2445540

Group type: EXPERIMENTAL
Intervention: Anisoylated plasminogen streptokinase activator complex (APSAC)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 86
Study: 29924310

Group type: EXPERIMENTAL
Intervention: Tyvek® Classic Plus
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: HF Estufa polyamide (Brisa®)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Tychem® C Standard
Number of subjects: 42
Study: 26868123

Group type: EXPERIMENTAL
Intervention: 4000 IU D3 daily for 6 months
Number of subjects: 116

Group type: COMPARATOR
Intervention: 600 IU D3 daily for 6 months
Number of subjects: 116
Study: 25775024

Group type: EXPERIMENTAL
Intervention: CHOP chemotherapy in combination with Ofatumumab (CHOP-O)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ofatumumab maintenance therapy
Number of subjects: 25
Study: 23090424

Group type: EXPERIMENTAL
Intervention: Intermittent drain clamping with injection of diluted epinephrine solution (Group I)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nonclamping without injection of diluted epinephrine solution (Group II)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 21256799

Group type: EXPERIMENTAL
Intervention: Pramipexole (optimized at 0.125, 0.25, 0.50, or 0.75 mg/day)
Number of subjects: 755

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 755
Study: 19376750

Group type: EXPERIMENTAL
Intervention: Light pressure effleurage massage
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control visit (equal amount of attention)
Number of subjects: 30
Study: 16569981

Group type: EXPERIMENTAL
Intervention: Customized videotapes
Number of subjects: 214

Group type: COMPARATOR
Intervention: Standard videotapes
Number of subjects: 214

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 214
Study: 12920388

Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 19
Study: 11104118

Group type: EXPERIMENTAL
Intervention: 0.5 g/kg alcohol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1.0 g/kg alcohol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9114143

Group type: EXPERIMENTAL
Intervention: Clindamycin and ciprofloxacin
Number of subjects: 131

Group type: COMPARATOR
Intervention: Ceftriaxone and doxycycline
Number of subjects: 131
Study: 1586604

Group type: EXPERIMENTAL
Intervention: Chemotherapy (cyclophosphamide 1,000 mg m‐2 i.v., doxorubicin 50 mg m‐2 i.v., vincristine 1.4 mg m‐2 i.v., and prednisolone 40 mg orally for 5 days, given 3 weekly for four cycles) + Radiotherapy (CHOP + RT)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Radiotherapy alone (RT)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Chemotherapy (CHOP + RT)
Number of subjects: 76
Study: 2872569

Group type: EXPERIMENTAL
Intervention: L-363,586 (10 micrograms/hr)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Somatostatin (200 micrograms/hr)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 29346831

Group type: EXPERIMENTAL
Intervention: Dual external ventricular drain (EVD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single external ventricular drain (EVD)
Number of subjects: 0
Study: 27570088

Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (1000 mg single dose)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Standard care (observation)
Number of subjects: 201
Study: 24170101

Group type: EXPERIMENTAL
Intervention: Transdermal estrogen treatment for 3 weeks
Number of subjects: 20
Study: 22904179

Group type: EXPERIMENTAL
Intervention: GH 2 mg/m(2) · d during puberty
Number of subjects: 121

Group type: COMPARATOR
Intervention: GH/GnRHa
Number of subjects: 121
Study: 21275161

Group type: EXPERIMENTAL
Intervention: Three-step acupuncture (TSA) combined with small dosage antipsychotic
Number of subjects: 60

Group type: COMPARATOR
Intervention: Full-dose antipsychotic
Number of subjects: 60
Study: 18955423

Group type: EXPERIMENTAL
Intervention: Functional strength training group (n = 8)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Training-as-usual group (n = 10)
Number of subjects: 18
Study: 16941276

Group type: EXPERIMENTAL
Intervention: IL-18 levels in subjects with arterial hypertension
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Correlation of waist to hip ratio with IL-18
Number of subjects: 261

Group type: COMPARATOR
Intervention: IL-18 levels in obese vs normal-weight individuals
Number of subjects: 261
Study: 12883781

Group type: EXPERIMENTAL
Intervention: Modified long gamma nail (LGN10)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Long gamma nail (LGN11)
Number of subjects: 50
Study: 10871975

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg once daily
Number of subjects: 359

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 359